Phathom Pharma Upgraded by Barclays to Overweight $18 Target
Barclays lifts Phathom Pharmaceuticals to Overweight with an $18 target, citing a stronger 2026 revenue trajectory an...
Explore why a budget calculator may be inaccurate and how to diagnose common sources of error, then implement corrective steps.
19,411 articlesBarclays lifts Phathom Pharmaceuticals to Overweight with an $18 target, citing a stronger 2026 revenue trajectory an...
A scammer in Memphis posed as a lawyer and drained hundreds of thousands from people in legal trouble. This article e...
Florida’s housing to-do list in 2026 features divergent markets, tighter loan conditions, and price concessions as bu...
Two market leaders just lit up a golden cross, drawing investor attention to Best Buy and Visa. Here’s a concise read...
A Crinetics director sells 5,000 shares as the stock dips. This guide breaks down what insider moves really mean for ...
Visa is exploring an internal stablecoin platform that would give its enterprise clients access to Origin Protocol's ...
Gas prices surged this week, lifting the national average price by about 33 cents. The rise comes as refinery mainten...
SoFi Technologies is not your average fintech. This article explores how customer growth, cross-sell momentum, and pr...
Oil weakness and a tech-led stock rally push the VIX toward the 17 level as traders return to equities.
June's jet deliveries offer a clear signal about Boeing's momentum as it nears the July earnings report. This article...
Goldman Sachs' latest research paints a paradox: trillions are pouring into AI infrastructure, but returns remain mur...
Rocket Lab shares hover near $67 as July odds tilt toward downside. This story breaks down what prediction markets be...